Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raffit Hassan

Showing results (51-60 of 150) with videos related to

Pageof 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
Humoral immune response to mesothelin in mesothelioma and ovarian cancer patientsMitchell Ho, Raffit Hassan, Jingli Zhang, et al.
Plos One|August 15, 2014
Megakaryocytic potentiating factor and mature mesothelin stimulate the growth of a lung cancer cell line in the peritoneal cavity of miceJingli Zhang, Tapan K Bera, Wenhai Liu, et al.
The American Journal of Pathology|February 12, 2013
New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomasBrooke T Mossman, Arti Shukla, Nicholas H Heintz, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 4, 2012
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopesWenhai Liu, Masanori Onda, Byungkook Lee, et al.
Molecular Cancer Therapeutics|October 8, 2015
Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing TumorsRonit Mazor, Jingli Zhang, Laiman Xiang, et al.
European Journal of Haematology|September 7, 2007
Mesothelin, a possible target for immunotherapy, is expressed in primary AML cellsDaniel Steinbach, Masanori Onda, Astrid Voigt, et al.
Biorxiv : the Preprint Server for Biology|June 26, 2025
Temporal mapping of the anti-tumor effects of nanobody-based MSLN.CAR-T cell therapy in metastatic solid tumorsChaido Stathopoulou, Mingming Zhao, Qun Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesotheliomaMasanori Onda, Satoshi Nagata, Mitchell Ho, et al.
JCO Oncology Practice|March 7, 2025
Treatment of Pleural Mesothelioma: ASCO Guideline Clinical InsightsHedy L Kindler, Ibiayi Dagogo-Jack, Marc de Perrot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2007
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancersRaffit Hassan, Susie Bullock, Ahalya Premkumar, et al.
Pageof 15

Showing results (51-60 of 150) with videos related to

Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
Humoral immune response to mesothelin in mesothelioma and ovarian cancer patientsMitchell Ho, Raffit Hassan, Jingli Zhang, et al.
Plos One|August 15, 2014
Megakaryocytic potentiating factor and mature mesothelin stimulate the growth of a lung cancer cell line in the peritoneal cavity of miceJingli Zhang, Tapan K Bera, Wenhai Liu, et al.
The American Journal of Pathology|February 12, 2013
New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomasBrooke T Mossman, Arti Shukla, Nicholas H Heintz, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 4, 2012
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopesWenhai Liu, Masanori Onda, Byungkook Lee, et al.
Molecular Cancer Therapeutics|October 8, 2015
Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing TumorsRonit Mazor, Jingli Zhang, Laiman Xiang, et al.
European Journal of Haematology|September 7, 2007
Mesothelin, a possible target for immunotherapy, is expressed in primary AML cellsDaniel Steinbach, Masanori Onda, Astrid Voigt, et al.
Biorxiv : the Preprint Server for Biology|June 26, 2025
Temporal mapping of the anti-tumor effects of nanobody-based MSLN.CAR-T cell therapy in metastatic solid tumorsChaido Stathopoulou, Mingming Zhao, Qun Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesotheliomaMasanori Onda, Satoshi Nagata, Mitchell Ho, et al.
JCO Oncology Practice|March 7, 2025
Treatment of Pleural Mesothelioma: ASCO Guideline Clinical InsightsHedy L Kindler, Ibiayi Dagogo-Jack, Marc de Perrot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2007
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancersRaffit Hassan, Susie Bullock, Ahalya Premkumar, et al.
Pageof 15